This trial is a randomized, double-blind, placebo controlled trial designed to test whether
two years treatment of preschool children aged 2-3 years of age at high risk for asthma with
omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as
reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2
year observation period off study drug.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Children's Hospital Wanda Phipatanakul
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)